Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Henri S. Lichenstein"'
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Supplemental Table S2 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40168a14b344b02e05f1362451352fda
https://doi.org/10.1158/1535-7163.22484604.v1
https://doi.org/10.1158/1535-7163.22484604.v1
Data from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the current investigation, we examined the activity of PXD101, a potent histone deacetylase inhibitor, used alone or in combination with clinically relevant chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0c4d95e56c2198a6e958a16e2a4799
https://doi.org/10.1158/1535-7163.c.6531480
https://doi.org/10.1158/1535-7163.c.6531480
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Supplemental Table S4 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce895b832a64a2182b82afc57be94b2
https://doi.org/10.1158/1535-7163.22484598
https://doi.org/10.1158/1535-7163.22484598
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Supplemental Table S1 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::178cdf95bb7366f14e09153a747c2b2b
https://doi.org/10.1158/1535-7163.22484607.v1
https://doi.org/10.1158/1535-7163.22484607.v1
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Supplemental Table S3 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f97a5bb65dc6589897dbff48faa0e3
https://doi.org/10.1158/1535-7163.22484601.v1
https://doi.org/10.1158/1535-7163.22484601.v1
Autor:
Sampath Kumar, Ferenc L. Boldog, Michael Jeffers, James Ritchie, Evan Mills, Paul W. Finn, Stanny C Berghs, Maxwell Sehested, Henri S. Lichenstein, Xiaozhong Qian, Craig Hackett, Nagma Khan, Nicholai Khramtsov, Anthony Tumber, Peter Buhl Jensen, Laura S. Collins, Nessa Carey
Publikováno v:
Biochemical Journal. 409:581-589
The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription. While HDACs can be subdivided into three main classes, the class I, class II and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34362962d8532db35faf9d6863b4158
https://doi.org/10.1042/bj20070779
https://doi.org/10.1042/bj20070779
Autor:
Jette Tjørnelund, Cindy McCully, Frank M. Balis, Katherine E. Warren, Henrik Dvinge, Henri S. Lichenstein, Maxwell Sehested
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:433-437
Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a816dc43774cfab617d213893cd4ea
https://doi.org/10.1007/s00280-007-0622-5
https://doi.org/10.1007/s00280-007-0622-5
Autor:
Iris Behrmann, Juergen Floege, Henri S. Lichenstein, A. Chaudhuri, C. R. van Roeyen, Dirk Bokemeyer, C. E. Pena, Frank Strutz, William J. LaRochelle, Tammo Ostendorf, Bernd Denecke
Publikováno v:
Kidney International. 69(8):1393-1402
Platelet-derived growth factor (PDGF)-BB and PDGF-DD mediate mesangial cell proliferation in vitro and in vivo. While PDGF-BB is a ligand for the PDGF alpha- and beta-receptor chains, PDGF-DD binds more selectively to the beta-chain, suggesting poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39438cb2bca7e891f74941747479c654
Autor:
Jeffrey D. Peterson, Gadi Gazit-Bornstein, Claudia R.C. van Roeyen, William J. LaRochelle, Avin J. Hamad, Gerlinde Chan, Xiao-Chi Jia, Frank Eitner, Tammo Ostendorf, Jennifer Macaluso, Bruce Keyt, Jürgen Floege, Henri S. Lichenstein, Uta Kunter
Publikováno v:
Journal of the American Society of Nephrology. 14:2237-2247
PDGF-B is of central importance in mesangioproliferative diseases. PDGF-D, a new PDGF isoform, like PDGF-B, signals through the PDGF betabeta-receptor. The present study first determined that PDGF-D is mitogenic for rat mesangial cells and is not inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6edfb804e08cfc459288399624175c85
https://doi.org/10.1097/01.asn.0000083393.00959.02
https://doi.org/10.1097/01.asn.0000083393.00959.02
Publikováno v:
Expert Opinion on Therapeutic Targets. 6:469-482
The fibroblast growth factor (FGF) family of signalling molecules and its receptors (FGFRs) contribute to normal developmental and physiological processes. However, the subversion of this powerful growth stimulatory pathway has been implicated in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d578cb8681f95a2f4e5a592e6116a9d1
https://doi.org/10.1517/14728222.6.4.469
https://doi.org/10.1517/14728222.6.4.469